Mitogen-activated protein kinase pathway inhibitors: inhibitors for diseases?

Xu WANG MS1,Xiao-Wei GONG MD, PhD2,Yong JIANG MD, PhD2,Yu-Hua LI PhD3,

PDF(258 KB)
PDF(258 KB)
Front. Med. ›› 2010, Vol. 4 ›› Issue (1) : 46-53. DOI: 10.1007/s11684-010-0010-0
Research articles
Research articles

Mitogen-activated protein kinase pathway inhibitors: inhibitors for diseases?

  • Xu WANG MS1,Xiao-Wei GONG MD, PhD2,Yong JIANG MD, PhD2,Yu-Hua LI PhD3,
Author information +
History +

Abstract

Mitogen-activated protein kinase (MAPK) signaling pathway, one of the most important signaling pathways in eukaryotic organism, is involved in multiple cellular events such as cell growth, differentiation, and apoptosis. MAPK is of great importance to the normal function of organisms, while its dysfunction results in various diseases. So far, inhibitors specifically against each subfamilies of MAP kinase have been developed, while more endeavors are needed to discover the compounds selectively targeting a particular subfamily member. Most of the kinase inhibitors exert their functions in an ATP-competitive way or a non-ATP-competitive way. Further studies on the effective mechanism of the MAPK inhibitors and their therapeutic roles in the treatment of diseases are helpful for the illumination of MAP kinase function, the development of novel inhibitors, and the therapy of diseases caused by the dysfunction of the MAPK pathway.

Keywords

mitogen-activated protein kinase / drug target / inhibitor / signal transduction / disease

Cite this article

Download citation ▾
Xu WANG MS, Xiao-Wei GONG MD, PhD, Yong JIANG MD, PhD, Yu-Hua LI PhD,. Mitogen-activated protein kinase pathway inhibitors: inhibitors for diseases?. Front. Med., 2010, 4(1): 46‒53 https://doi.org/10.1007/s11684-010-0010-0
AI Summary AI Mindmap
PDF(258 KB)

Accesses

Citations

Detail

Sections
Recommended

/